Literature DB >> 8176090

Percutaneous transatrial mitral commissurotomy: immediate and intermediate results.

R Arora1, G S Kalra, G S Murty, V Trehan, N Jolly, J C Mohan, K K Sethi, M Nigam, M Khalilullah.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the immediate and follow-up results of percutaneous transatrial mitral commissurotomy in 600 patients with rheumatic mitral stenosis.
BACKGROUND: Percutaneous transatrial mitral commissurotomy has emerged as an effective nonsurgical technique for patients with symptomatic mitral stenosis. Several studies have shown that the immediate results are comparable to closed and open mitral valvotomy.
METHODS: Percutaneous transatrial mitral commissurotomy was performed in 600 patients with rheumatic mitral stenosis by the double-balloon (290 patients [48.3%]) and flow-guided Inoue balloon (310 patients [51.7%]) techniques. There were 154 male (25.6%) and 446 female (77.4%) patients with a mean [+/- SD] age of 27 +/- 8 years (range 8 to 60). Atrial fibrillation was present in 26 patients (4.3%), mitral regurgitation < or = grade 2 in 62 (10.3%) and densely calcific valve in 12 (2%). All patients had clinical and echocardiographic (two-dimensional, continuous wave Doppler, color flow imaging) follow-up at 3-month intervals.
RESULTS: Percutaneous transatrial mitral commissurotomy was successful in 589 patients (98.1%), and optimal commissurotomy was achieved in 562 (93.6%), with an increase in mitral valve area from (mean +/- SD) 0.75 +/- 0.18 to 2.2 +/- 0.38 cm2 (p < 0.001) and a decrease in transmitral end-diastolic gradient from 27.3 +/- 6.1 to 3.8 +/- 4.2 mm Hg (p < 0.001). Mitral regurgitation developed or increased in 208 patients (34.6%). Six patients (1%) with mitral regurgitation required mitral valve replacement. Cardiac tamponade occurred in 8 patients (1.3%). Six patients (1%) died. Restenosis developed in 10 patients (1.7%) during a mean follow-up period of 37 +/- 8 months (range 6 to 66).
CONCLUSIONS: Percutaneous transatrial mitral commissurotomy is an effective, safe procedure with gratifying intermediate results. It should be considered the treatment of choice for rheumatic mitral stenosis.

Entities:  

Mesh:

Year:  1994        PMID: 8176090     DOI: 10.1016/0735-1097(94)90374-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Percutaneous balloon mitral commissurotomy during pregnancy.

Authors:  M Ben Farhat; H Gamra; F Betbout; F Maatouk; M Jarrar; F Addad; M Tiss; S Hammami; I Chahbani; R Thaalbi
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 2.  The long-term outcome of balloon valvuloplasty for mitral stenosis.

Authors:  Bernard Iung; Alec Vahanian
Journal:  Curr Cardiol Rep       Date:  2002-03       Impact factor: 2.931

3.  Percutaneous transvenous mitral commissurotomy in elderly mitral stenosis patients. A retrospective study at shahid gangalal national heart centre, bansbari, kathmandu, Nepal.

Authors:  Chandra Mani Adhikari; Rabi Malla; Rajib Rajbhandari; Yadav Kumar Bhatta; Arun Maskey; Suman Thapaliya; Prakash Gurung; Kc Man Bahadur
Journal:  Maedica (Buchar)       Date:  2013-09

4.  New Scores for the Assessment of Mitral Stenosis Using Real-Time Three-Dimensional Echocardiography.

Authors:  Osama I I Soliman; Ashraf M Anwar; Ahmed K Metawei; Jackie S McGhie; Marcel L Geleijnse; Folkert J Ten Cate
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-07-09

5.  Mitral regurgitation after percutaneous balloon mitral valvotomy in patients with rheumatic mitral stenosis: a single-center study.

Authors:  Naser Aslanabadi; Mehrnoush Toufan; Rezvaneyeh Salehi; Azin Alizadehasl; Samad Ghaffari; Bahram Sohrabi; Ahmad Separham; Ataolaah Manafi; Mohammad Bagher Mehdizadeh; Afshin Habibzadeh
Journal:  J Tehran Heart Cent       Date:  2014-07-03

Review 6.  Meta-Analysis of the Incidence, Prevalence, and Correlates of Atrial Fibrillation in Rheumatic Heart Disease.

Authors:  Jean Jacques Noubiap; Ulrich Flore Nyaga; Aude Laetitia Ndoadoumgue; Jan René Nkeck; Anderson Ngouo; Jean Joel Bigna
Journal:  Glob Heart       Date:  2020-05-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.